Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone

Prevalence of Molecular Markers of Resistance... | Gates Open Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://gatesopenresearch.org/js/vendor/ckeditor/' window.reactTheme = 'gates'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); Skip to content Gates Open Research file_upload Submit via VeriXiv search clear search menu close clear Search Browse Gateways & Collections How to Publish Submit via VeriXiv My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Publication Charges Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Contact Blog My Account Submissions Content and Tracking Alerts My Details Sign In Submit via VeriXiv { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://gatesopenresearch.org/articles/9-81" }, "headline": "Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria...", "datePublished": "2025-10-08T14:26:09", "dateModified": "2025-10-08T14:26:09", "author": [ { "@type": "Person", "name": "Haily Chen" }, { "@type": "Person", "name": "Kwabena Owusu-Kyei" }, { "@type": "Person", "name": "Augustin E. Fombah" }, { "@type": "Person", "name": "Julian Williams" }, { "@type": "Person", "name": "Carla García-Fernández" }, { "@type": "Person", "name": "Eduard Rovira-Vallbona" }, { "@type": "Person", "name": "Andreu Bofill" }, { "@type": "Person", "name": "Llorenç Quintó" }, { "@type": "Person", "name": "Antía Figueroa-Romero" }, { "@type": "Person", "name": "Falama Mac-Abdul" }, { "@type": "Person", "name": "Mohamed Samai" }, { "@type": "Person", "name": "Alfredo Mayor" }, { "@type": "Person", "name": "Clara Menéndez" } ], "publisher": { "@type": "Organization", "name": "Gates Open Research", "logo": { "@type": "ImageObject", "url": "https://gatesopenresearch.org/img/AMP/Gates_image.png", "height": 600, "width": 47 } }, "image": { "@type": "ImageObject", "url": "https://gatesopenresearch.org/img/AMP/Gates_image.png", "height": 1200, "width": 94 }, "description": " Background Monitoring parasite resistance to antimalarial drugs is essential for detecting potential changes in drug efficacy. This study assessed the prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine (SP), chloroquine, and artemisinin in Sierra Leone, where SP is used for intermittent preventive treatment in pregnancy (IPTp) and perennial malaria chemoprevention (PMC) in young children, while artemisinin is used to treat malaria episodes. Methods A cross-sectional survey was conducted between June and August 2021 in three districts of Sierra Leone. A total of 440 febrile children aged 2-5 years attending the health facilities were screened for P. falciparum malaria using a rapid diagnostic test, and 300 participants with positive RDT were enrolled. Capillary blood samples were collected as dried blood spots, analyzed using quantitative PCR to confirm P. falciparum, and sequenced for resistance markers in pfdhfr, pfdhps, pfcrt, pfmdr1, and pfK13. Results Of 298 blood samples, 237 (79.5%) were qPCR-positive and 230 samples were successfully genotyped. The pfdhfr triple mutant (N51I/C59R/S108N) was detected in 99.5% of samples (217/218), while pfdhps mutations A437G and K540E were detected in 92.1% (211/229) and 19.1% (42/220), respectively. The pfdhfr/dhps quintuple mutant (triple mutant + A437G/K540E) prevalence was 4.6% (7/151), and no sextuple mutants (quintuple + pfdhps-A581G) were observed. Chloroquine resistance-associated mutations in pfcrt (CVIET haplotype) were detected in 36.6% of samples, while pfmdr1 mutations at codon 86, 184, 1042, and 1246 occurred in 2.3%, 71.7%, 0.9% and 1.8%, respectively. No validated pfK13 markers of artemisinin resistance were detected. Conclusion In this study, the sustained low prevalence of pfdhfr/dhps quintuple mutant justifies the continued use of SP- containing IPTp and PMC, as well as its expansion in the country into the second year of life with additional SP doses. Importantly, no validated pfK13 markers were found supporting the use of artemisinin-based combination therapies in Sierra Leone. Trial registration Clinicaltrials.gov NCT04235816. Registered on January 17, 2020 " } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://gatesopenresearch.org/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://gatesopenresearch.org/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://gatesopenresearch.org/articles/9-81/v1", "name": "Prevalence of Molecular Markers of Resistance to Antimalarial Drugs..." } } ] } Home Browse Prevalence of Molecular Markers of Resistance to Antimalarial Drugs... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Chen H, Owusu-Kyei K, Fombah AE et al. Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone . Gates Open Res 2025, 9 :81 ( https://doi.org/10.12688/gatesopenres.16367.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Research Article Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone Haily Chen 1-3 * , Kwabena Owusu-Kyei https://orcid.org/0009-0006-3733-7936 1,2,4 * , Augustin E. Fombah 1,2,4,5 , [...] Julian Williams 4 , Carla García-Fernández 1 , Eduard Rovira-Vallbona 1 , Andreu Bofill 1 , Llorenç Quintó https://orcid.org/0000-0001-9992-6951 1,3,6 , Antía Figueroa-Romero https://orcid.org/0000-0003-4682-1421 1-3 , Falama Mac-Abdul 5 , Mohamed Samai 4,5 , Alfredo Mayor 1-3,6,7 , Clara Menéndez https://orcid.org/0000-0002-2641-6907 1,3,6,8 Haily Chen 1-3 * , Kwabena Owusu-Kyei https://orcid.org/0009-0006-3733-7936 1,2,4 * , [...] Augustin E. Fombah 1,2,4,5 , Julian Williams 4 , Carla García-Fernández 1 , Eduard Rovira-Vallbona 1 , Andreu Bofill 1 , Llorenç Quintó https://orcid.org/0000-0001-9992-6951 1,3,6 , Antía Figueroa-Romero https://orcid.org/0000-0003-4682-1421 1-3 , Falama Mac-Abdul 5 , Mohamed Samai 4,5 , Alfredo Mayor 1-3,6,7 , Clara Menéndez https://orcid.org/0000-0002-2641-6907 1,3,6,8 * Equal contributors PUBLISHED 08 Oct 2025 Author details Author details 1 ISGlobal, Barcelona, Spain 2 Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona, Barcelona, Spain 3 Centro de Investigacion Biomedica en Red de Epidemiologia y Salud Publica, Madrid, Community of Madrid, Spain 4 University of Sierra Leone College of Medicine and Allied Health Sciences, Freetown, Western Area, Sierra Leone 5 Ministry of Health, Freetown, Sierra Leone 6 Centro de Investigação em Saude de Manhiça, Manhiça, Maputo Province, Mozambique 7 Department of Physiological Sciences, Faculty of Medicine, Universidade Eduardo Mondlane, Maputo, Mozambique 8 Servicio de Salud Internacional, Hospital Clínic de Barcelona, Barcelona, Spain Haily Chen Roles: Conceptualization, Investigation, Methodology, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Kwabena Owusu-Kyei Roles: Conceptualization, Investigation, Methodology, Project Administration, Resources, Supervision, Writing – Review & Editing Augustin E. Fombah Roles: Investigation, Project Administration, Writing – Review & Editing Julian Williams Roles: Data Curation, Investigation, Supervision Carla García-Fernández Roles: Data Curation, Investigation, Supervision Eduard Rovira-Vallbona Roles: Conceptualization, Methodology, Software, Validation, Writing – Review & Editing Andreu Bofill Roles: Conceptualization, Data Curation, Formal Analysis, Software Llorenç Quintó Roles: Conceptualization, Formal Analysis, Software Antía Figueroa-Romero Roles: Formal Analysis, Writing – Review & Editing Falama Mac-Abdul Roles: Project Administration, Resources Mohamed Samai Roles: Conceptualization, Project Administration, Resources Alfredo Mayor Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Resources, Supervision, Validation, Writing – Review & Editing Clara Menéndez Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Resources, Supervision, Writing – Review & Editing OPEN PEER REVIEW REVIEWER STATUS AWAITING PEER REVIEW Originally published as a preprint: https://doi.org/10.12688/verixiv.1155.1 Abstract Background Monitoring parasite resistance to antimalarial drugs is essential for detecting potential changes in drug efficacy. This study assessed the prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine (SP), chloroquine, and artemisinin in Sierra Leone, where SP is used for intermittent preventive treatment in pregnancy (IPTp) and perennial malaria chemoprevention (PMC) in young children, while artemisinin is used to treat malaria episodes. Methods A cross-sectional survey was conducted between June and August 2021 in three districts of Sierra Leone. A total of 440 febrile children aged 2-5 years attending the health facilities were screened for P. falciparum malaria using a rapid diagnostic test, and 300 participants with positive RDT were enrolled. Capillary blood samples were collected as dried blood spots, analyzed using quantitative PCR to confirm P. falciparum, and sequenced for resistance markers in pfdhfr, pfdhps, pfcrt, pfmdr1, and pfK13. Results Of 298 blood samples, 237 (79.5%) were qPCR-positive and 230 samples were successfully genotyped. The pfdhfr triple mutant (N51I/C59R/S108N) was detected in 99.5% of samples (217/218), while pfdhps mutations A437G and K540E were detected in 92.1% (211/229) and 19.1% (42/220), respectively. The pfdhfr/dhps quintuple mutant (triple mutant + A437G/K540E) prevalence was 4.6% (7/151), and no sextuple mutants (quintuple + pfdhps -A581G) were observed. Chloroquine resistance-associated mutations in pfcrt (CVIET haplotype) were detected in 36.6% of samples, while pfmdr1 mutations at codon 86, 184, 1042, and 1246 occurred in 2.3%, 71.7%, 0.9% and 1.8%, respectively. No validated pfK13 markers of artemisinin resistance were detected. Conclusion In this study, the sustained low prevalence of pfdhfr/dhps quintuple mutant justifies the continued use of SP- containing IPTp and PMC, as well as its expansion in the country into the second year of life with additional SP doses. Importantly, no validated pfK13 markers were found supporting the use of artemisinin-based combination therapies in Sierra Leone. Trial registration Clinicaltrials.gov NCT04235816. Registered on January 17, 2020 READ ALL READ LESS Keywords malaria, chemoprevention, resistance, IPTi, PMC, U5, sulfadoxine-pyrimethamine, Sierra Leone Corresponding Author(s) Kwabena Owusu-Kyei ( [email protected] ) Antía Figueroa-Romero ( [email protected] ) Close Corresponding authors: Kwabena Owusu-Kyei, Antía Figueroa-Romero Competing interests: No competing interests were disclosed. Grant information: This work was financially supported by the Gates Foundation (OPP1196642 and INV-067310, A.M.), La Caixa Foundation and the Departament d’Universitats i Recerca de la Generalitat de Catalunya (AGAUR; grant 2021 SGR 01517, A.M.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Copyright: © 2025 Chen H et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Chen H, Owusu-Kyei K, Fombah AE et al. Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone . Gates Open Res 2025, 9 :81 ( https://doi.org/10.12688/gatesopenres.16367.1 ) First published: 08 Oct 2025, 9 :81 ( https://doi.org/10.12688/gatesopenres.16367.1 ) Latest published: 08 Oct 2025, 9 :81 ( https://doi.org/10.12688/gatesopenres.16367.1 ) Introduction Malaria accounted for an estimated 246 million cases and 569,000 deaths globally in 2023. 1 The African region contributed 95% of malaria cases and 96% of malaria-related deaths, with children under five years of age (U5) being disproportionately affected. 1 Effective treatment and prevention of Plasmodium falciparum infections with antimalarial drugs are critical for malaria control and elimination. To treat P. falciparum malaria, the WHO recommends six artemisinin-based combination therapies (ACTs): artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ), artesunate-mefloquine (ASMQ), dihydroartemisinin-piperaquine (DP), artesunate-sulfadoxine/pyrimethamine (ASSP), and artesunate-pyronaridine (AP). 2 Chemoprevention is a key strategy for malaria control in areas with stable transmission. The WHO recommends three chemoprevention approaches involving sulfadoxine-pyrimethamine (SP) administered at curative doses, irrespective of infection status: intermittent preventive treatment in pregnancy (IPTp), seasonal malaria chemoprevention (SMC), and intermittent preventive treatment in infants (IPTi), now referred to as Perennial Malaria Chemoprevention (PMC). 2 SP remains the preferred drug for IPTp, PMC, and SMC (the latter co-packaged with amodiaquine) due to its safety, tolerability, and cost-effectiveness in reducing malaria-related morbidity and neonatal mortality. 3 , 4 Experiences of SP resistance in Southeast Asia regularly raised concerns about its use for malaria prevention in Africa. 5 Pyrimethamine and other antifolates target P. falciparum dihydrofolate reductase (DHFR), while sulfadoxine and other sulfonamides act on dihydropteroate synthase (DHPS). Resistance arises from single nucleotide polymorphisms (SNPs) in the dhfr and dhps genes. Mutations in dhfr at codons 51, 59, 108, and 164 confer resistance to pyrimethamine, while SNPs in dhps at codons 437, 540, 581, and 613 drive resistance to sulfadoxine. 6 – 8 These mutations typically accumulate stepwise, leading to stronger drug resistance and the dhfr/dhps quintuple mutant (51I, 59R, 108N + 437G, 540E) has been associated with SP treatment failure. 9 , 10 On the other hand, a pooled study suggested that in areas where the sextuple mutant (quintuple + dhps 581G) is present, the effectiveness of IPTp with SP may decline when the prevalence of this mutation exceeds 10%. 11 Currently, validated resistance markers for other antimalarial drugs include some single nucleotide polymorphisms (SNPs) in the kelch 13 gene, providing partial resistance to artemisinin, 12 and the K76T in the pfcrt gene ( P. falciparum chloroquine-CQ- resistance transporter) regarding chloroquine. 13 In Sierra Leone, malaria is endemic with perennial transmission and seasonal peaks occurring from May to October. Over 90% of cases are caused by P. falciparum , with pregnant women and U5 being the most vulnerable to the infection. 14 Malaria prevalence in U5 measured by rapid diagnostic tests (RDTs), declined from 40% in 2016 to 22% in 2021. 15 , 16 Malaria-attributed mortality has declined significantly since 2000 in Sierra Leone, driven by free diagnostic testing, widespread deployment of insecticide-treated bed nets, and malaria chemoprevention programs. Nationwide IPTp has been implemented in antenatal clinics since 2014 and PMC has been integrated into the Expanded Program on Immunization (EPI) alongside immunization contacts at 10 weeks, 14 weeks, and 9 months, since 2018. Chloroquine, introduced as the first-line treatment for uncomplicated malaria in the 1940s, was replaced in 2004 with artemether-lumefantrine. 17 The main objective of this study is to report on the prevalence of molecular markers associated with SP resistance in Sierra Leone seven and three years after the nationwide implementation of IPTp and PMC, respectively. As a secondary objective, we also assessed the prevalence of molecular markers associated with resistance to chloroquine and artemisinin. 17 Methodology Study design and sample size The study was designed as a cross-sectional, health facility-based survey conducted in three districts of Sierra Leone’s Northern Province: Tonkolili, Bombali, and Port Loko. A sample size of 300 children was calculated to detect an ≥8.4% increase in SP resistance prevalence, assuming a baseline prevalence of 10% and accounting for a 10% potential sample loss. 15 Participants recruitment and sample collection From June to August 2021, children attending outpatient departments of five health facilities in the study area were screened for eligibility. Children who met the following criteria were invited to participate in the study: (i) aged two to five years old, (ii) an axillary temperature ≥37.5 °C or a history of fever in the preceding 24 hours, iii) no signs of severe malaria, 2 iv) and a positive result for malaria with an HPR (histidine-rich protein) 2-based rapid diagnostic test (RDT) (Malaria Ag P.f/Pan, SD Bioline TM , Gyeonggi-do, Republic of Korea). The RDT used in this study is listed in the WHO-prequalified in vitro Diagnostic Products used by the Sierra Leone National Malaria Control Program. 18 After written informed consent was obtained from caretakers, a questionnaire was administered to collect socio-demographic information and clinical information. Enrolled children underwent clinical assessments, including anthropometric measurements (weight, height/length, and mid-upper arm circumference [MUAC]). Finger-prick blood samples were collected on Whatman ® FTA filter papers in the form of Dried Blood Spots (DBSs), labeled with unique identifiers, were dried completely for 24 hours at room temperature, and stored at 4°C with silica gel until shipment to the Hospital Clínic in Barcelona where they were stored at -20°c until further molecular analysis. Laboratory procedures Parasite genomic DNA was extracted from one 5 mm diameter punch from DBS using a Tween-Chelex-based protocol Merck, Ref: P1379 and C7901, 19 eluted in 100 ul of water, and subsequently quantified via qPCR targeting the pf18S ribosomal RNA (rRNA). 20 , 21 Sequencing of genetic markers of interest ( pfdhps , pfdhfr , pfcrt , pfmdr1 , and pfK13 ) was performed using the MAD4HatTeR multiplex amplicon sequencing panel (Paragon Genomics Inc, California, USA, Ref: PDG268), 22 following previously described procedures. 23 Libraries were paired-end sequenced in a NextSeq 2000 system with P1 reagents (Illumina, ref. 20050264). Fastq files were analyzed with MAD4HatTeR Nextflow-based pipeline version 0.1.8 24 using default parameters and the P. falciparum 3D7 genome as the reference for alternative allele calling, with the exception of pfdhps -A437G where the reference allele G was considered mutant. 25 Alleles with fewer reads than the maximum observed in any locus for negative controls were removed, along with alleles with a <1% within-sample frequency. Reconstruction of pfdhps double, pfdhfr triple and pfdhfr/pfdhps quintuple haplotypes was done for samples with no mixed genotypes at selected loci, to minimize phasing complexities. Statistical analysis Descriptive statistics summarized participant characteristics, with continuous variables reported as means ± standard deviations (SDs) and categorical variables as frequencies and percentages. Crude and multivariate logistic regression models were estimated using Firth’s Penalized Likelihood method to address data separation. 26 , 27 Profile Penalized-Log Likelihood was used to compute 95% confidence intervals (CIs). Anthropometric z-scores were computed using the LMS method and WHO reference charts, 28 with underweight defined as a weight-for-age z-score (WAZ) < -2. Analyses were performed using Stata/SE 18.0, with logistic regression conducted via the firthlogit program. 29 Ethics statement The study protocol and informed consent forms were approved by the Sierra Leone Ethics and Scientific Review Committee (dated August 9, 2020, no approval number) and the Hospital Clínic Research Ethics Committee (Barcelona, Spain) (Registration No: HCB/2020/0173, dated August 28, 2020). The study adheres to the Declaration of Helsinki. The study funder had no role in the design, data collection, analysis, interpretation, or manuscript writing. Consent Written informed consent for publication of the participants details was obtained from the participants’ guardian. Results Participants characteristics The study was conducted from June to August 2021. Out of 440 children attending the U5 outpatient department with signs and/or symptoms suggestive of malaria, 306 (74.5%) had a positive malaria RDT test. Of them, 300 (98.0%) were enrolled. A capillary sample was collected from these participants for molecular analysis ( Figure 1 ). The characteristics of the participants are shown in Table 1 . The majority of the children were from Tonkolili District (180, 60.0%) and the most common ethnic group was Themne (218, 72.7%). The participants’ mean age was 37.8 months (±10.5) and more than half of the participants (158, 52.7%) were male. A total of 62 (20.7%) children were underweight (defined as having a weight-for-age z-score (WAZ) <-2), and 78 (26.0%) children had an axillary temperature of ≥37.5°C. Most children (211, 70.3%) had slept under a bed net the previous night. A total of 113 (37.7%) children had received an antimalarial within the last month. The mean time since the participants’ last PMC dose was 27.3 months (±10.1). Figure 1. Survey profile. ICF: Informed consent form, RDT: Rapid diagnostic test. Table 1. Characteristics of study participants. Variable n/N Percentage or mean ± SD [N] District Bombali 20/300 6.7% Port Loko 100/300 33.3% Tonkolili 180/300 60.0% Age (months) 37.8 (10.5) [300] Sex Male 158/300 52.7% Female 142/296 47.3% Ethnic group Themne 218/296 72.7% Mende 22/296 7.3% Limba 18/296 6.0% Others 42/296 14.0% Underweight (WAZ <-2) No 238/300 79.3% Yes 62/300 20.7% Axillary temperature <37.5°C 222/300 74.0% ≥37.5°C 78/300 26.0% High parasitemia (≥500 parasites/μL) No 38/229 16.6% Yes 191/229 83.4% Bed net use No 88/300 29.3% Yes 211/300 70.3% Do not know 1/300 0.3% Antimalarials received within last month No 179/300 59.7% Yes 113/300 37.7% Do not know 8/300 2.7% On cotrimoxazole (more than 2 weeks) No 285/300 95.0% Yes 8/300 2.7% Do not know 7/300 2.3% Time since last SP dose (months) 27.3 (10.1) [214] Molecular markers of resistance to sulfadoxine-pyrimethamine, chloroquine and artemisinin derivatives Two (0.7%) out of the 300 dried blood spots samples were excluded due to laboratory processing errors. A total of 79.5% (237/298) blood samples were positive for P. falciparum by 18S qPCR. Among these, 229 (96.6%) samples were successfully sequenced at pfdhfr , and pfdhps loci (i.e. allele calls passed both negative controls and allele frequency filters). Of the sequenced blood samples, median parasite density was 13,850 parasites/μL (IQR: 372–79,219), ranging from 0.8 to 737,253 parasites/μL. Prevalence rates of molecular markers associated to antimalarial drug resistance are presented in Table 2 . Six mutations were found in the pfdhps gen (I431V, S436A, A437G, K540E and A613S). The single mutant alleles harboring 437A and 540E were found in 211/229 (92.1%; 95% CI 87.9–95.3) of the isolates and in 42/220 (19.1%; 95% CI 14.1–24.9) of isolates, respectively. The double 437/540 mutant allele haplotype was observed in 7/151 (4.6%; 95% CI 1.9–9.3) of isolates. Table 2. Molecular markers of resistance to sulfadoxine-pyrimethamine, chloroquine and artemisinin derivatives. Gene Marker n/N % (95% CI) pfdhps I431V 4/229 1.7% (0.5-4.4) S436A 125/229 54.6% (47.9-61.2) A437G 211/229 92.1% (87.9-95.3) K540E 42/220 19.1% (14.1-24.9) A581G 0/220 0% (0.0-1.7) A613S 47/217 21.7% (16.4-27.7) double 437-540 * 7/152 4.6 % (1.9-9.3) pfdhfr N51I 221/222 99.5% (97.5-100.0) C59R 221/222 99.5% (97.5-100.0) S108N 222/223 99.6% (97.5, 100.0) I164L 0/223 0% (0.0-1.6) Triple 51-59-108 * 217/218 99.5% (97.5-100.0) Pfdhps/dhfr Quintuple mutant * 7/151 4.6% (1.9-9.3) Sextuple mutant * 0/196 0% pfcrt 72-76 CVIET 82/224 36.6% (30.3-43.3) pfmdr1 N86Y 5/221 2.3% (0.7-5.2) Y184F 160/223 71.7% (65.4-77.6) S1034C 0/224 0% N1042D 2/224 0.9% (0.11-3.2) D1246Y 4/226 1.8% (0.48-4,47) 86-184-1034-1042-1246 NFSND 150/220 68.2% (61.6-74.3) pfK13 Validated mutations ** 0/219 0% * Only monoallelic infections are included. ** Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019). Geneva: World Health Organization; 2020. License: CC BY-NC-SA 3.0 IGO. 12 Regarding mutations in the pfdhfr gen , three mutations (N51I, C59R, S108N) were detected, with the triple N51I/C59R/S108N mutant allele present in 217/218 (99.5%; 95% CI 97.5-100) of the isolates. The pfdhps/pfdhfr quintuple mutant (N51I/C59R/S108N + A437G/K540E) was detected in 7/151 (4.6%; 95% CI: 1.9–9.3) of the isolates. No statistically significant associations were observed between the presence of quintuple mutations to SP and potential host risk factors ( Table 3 ). No sextuple mutant (N51I/C59R/S108N + A437G/K540E/A581S) was detected in any of the samples analysed. Table 3. Logistic regression of risk factors associated to P. falciparum infection with pfdhps / dhfr quintuple mutations * . Univariable models Multivariable model Variables Crude odds ratios (95% CI) P-value Adjusted odds ratios (95% CI) P-value District Bombali 1 0.7747 1 0.9019 Port Loko 0.58 (0.02-15.92) 0.59 (0.01-23.05) Tonkolili 1.14 (0.06-23.11) 0.95 (0.04-23.64) Age (months) 1.04 (0.97-1.11) 0.3092 1.02 (0.93-1.13) 0.6203 Female 2.62 (0.53-12.94) 0.2360 2.16 (0.45-10.43) 0.3393 Underweight (WAZ <-2) 1.02 (0.16-6.61) 0.9825 0.77 (0.12-5.00) 0.7885 Axillary temperature ≥37.5°C 0.74 (0.12-4.73) 0.7495 0.76 (0.13-4.58) 0.7616 High parasitemia (≥500 parasites/ul) 1.22 (0.19-7.85) 0.8325 1.23 (0.19-7.85) 0.8256 Bed net use 0.45 (0.10-2.08) 0.3052 0.50 (0.11-2.33) 0.3750 Antimalarials received last month 1.34 (0.29-6.23) 0.7048 1.53 (0.29-8.06) 0.6153 Time since last SP dose received (months) 1.05 (0.97-1.13) 0.2254 1.01 (0.93-1.11) 0.7917 * n = 101 observations. The pfcrt 72–76 CVIET haplotype that has been associated with P. falciparum resistance to chloroquine was detected in 82/224 (36.6%; 95% CI: 30.3-43.3) of the isolates. Regarding the pfmdr1 gene, four mutations were detected (N86Y, Y184F, N1042D and D1246Y) in 2.3% (5/221; 95% CI: 0.7-5.2), 71.7% (95% CI: 65.4-77.6), 0.9% (95% CI: 0.11-3.2) and 1.8% (95% CI: 0.48-4.47) of the tested isolates, respectively. No S1034C mutant was detected. Out of the 220 samples with a determinable full haplotype, 61 (27.7%, 95% CI: 21.9-34.1) were wild type for all five loci (NYSND haplotype), and 150 (68.2%; 95% CI: 61.6-74.3) were single mutants (codon 184, NFSND haplotype). No validated mutations in the pfk13 gene were detected in any of the 219 sequenced samples ( Table 2 ). Discussion The study was conducted in Sierra Leone seven and three years after the nationwide implementation of IPTp and PMC, respectively. Since 2015, artemisinin-lumefantrine (AL) is the first-line treatment for uncomplicated malaria in the country. The latest national Malaria Indicator Survey and a household survey from another study, both conducted in 2021, reported that more than half of pregnant women received at least three doses of IPTp, and nearly 60% of infants had received three PMC doses. 16 , 30 Despite the wide implementation of these SP-based strategies the findings from this study show a low prevalence (4.6%) of the pfdhfr/pfdhps quintuple mutant and no presence of the sextuple mutant. The prevalence of pfdhfr triple mutations was nearly fixed (99.5%), consistent with country reports from 2016 and 2018. 31 , 32 Nevertheless, the prevalence of the pfdhps/pfdhfr quintuple mutant was found at a lower prevalence (4.6%) in the current study as compared to the prevalence observed (10%) in the previous survey in 2016, with no data on quintuple mutant reported in 2018. 32 The low prevalence of the quintuple mutant in Sierra Leone aligns with rates reported in West Africa, like 15.4% in Guinea (2013-2016), 33 0% in Senegal (2010) 34 and 1.6% in Mali (2012). 35 The low prevalence of the quintuple mutant and the absence of the sextuple mutant in this study support the continued use of SP for chemoprevention in young children and pregnant women in Sierra Leone. Although the presence of SP resistance markers alone does not determine drug efficacy, especially when used for prevention, sustained drug pressure may drive these mutations toward saturation. 36 Therefore, regular monitoring of molecular resistance markers is important to understand how their prevalence affects drug effectiveness and to tailor malaria prevention programs. In this study, we also assessed the prevalence of molecular markers associated with chloroquine and artemisinin resistance in the country. Mutations in the pfcrt gene at codon 72-76 have been associated with P. falciparum tolerance to chloroquine and other 4-aminoquinolines such as amodiaquine and piperaquine. The pfcrt prevalence reported in this study is higher than the 22% observed in 2018 in a Southern district in the country, though the latter was based on a sample size of only 95 participants. 37 The pfcrt prevalence varies across West Africa, ranging from the highest in Liberia (87.9%, 2018), 38 a moderate level in the Democratic Republic of Congo (22.7%, 2019), 39 to low in Equatorial Guinea (2.8%, 2019) 40 and Togo (0.6%, 2021). 41 Mutations in the pfmdr1 gene also modulate parasite susceptibility to several ACT partner drugs (e.g. lumefantrine, mefloquine, and piperaquine). The predominant pfmdr1 NFSND haplotype detected in Sierra Leone is consistent with trends observed across West African countries that adopted artemether-lumefantrine (AL) and discontinued chloroquine as first-line treatment. 41 – 45 pfmdr1 mutations exhibit pleiotropic effects, with N86Y driving resistance to chloroquine and amodiaquine while sensitizing parasites to lumefantrine, mefloquine, and artemisinin derivatives. 46 – 49 These findings underscore the importance of molecular surveillance to optimize ACT use in different regions. Several mutations in the pfK13 gene are associated with artemisinin resistance. 12 However, none were detected in this study, indicating no molecular evidence of compromised efficacy of artemisinin and its derivatives in Sierra Leone. Nonetheless, the emergence of such mutations has been recently reported in Rwanda, 50 Uganda, 51 and the Democratic Republic of Congo, 52 mirroring the early stages of resistance observed in Southeast Asia. In that region, P. falciparum developed partial resistance to artemisinin-based combination therapies (ACT), leading to treatment failures and the spread of resistance strains. 5 To prevent a similar trend in Africa, regular surveillance and monitoring of artemisinin resistance are crucial. Nonetheless, the presence of resistance markers alone does not explain the reduced efficacy of antimalarial drugs. A meta-analysis of seven clinical trials concluded that IPTp with SP reduces placental malaria, low birthweight, and anemia in pregnant women, even in areas with SP treatment failure in children. 11 Factors such as patient adherence, metabolism, host immunity, and nutritional status also influence drug efficacy. These factors vary by individual, population, and region, requiring careful interpretation of molecular resistance markers and their impact on chemoprevention. 5 This study has some strengths and limitations. A key strength is its geographical coverage, spanning three districts in Sierra Leone’s Northern Province, making it more representative than previous surveys in 2016 and 2018, which were limited to the Kambia or Bo districts. 31 , 32 , 37 The study was limited by the fact that 20.5% (61/298) of blood samples from RDT-confirmed participants tested negative for P. falciparum by qPCR. These potential false positives may be due to the residual presence of HRP2 antigens in the bloodstream, which can persist in the blood for up to 28 days after infection clearance. 53 In addition, of the 61 participants with negative qPCR results, 28 reported having taken an antimalarial drug within the past month, which would be in line with the false-positive RDT results and better agrees with previously observed false positive rates of 10% with this RDT test. 54 Another explanation is a potential DNA degradation during sample preservation. In 2022, the WHO recommended additional PMC-SP doses to extend protection beyond the first year of life. 55 The current findings showing a low prevalence of the pfdhfr/pfdhps quintuple mutant and the absence of the sextuple mutant support the continued use of SP for IPTp and PMC, as well as the expansion of PMC with additional SP doses administered in the second year of life in Sierra Leone. Data availability Underlying data As the dataset contains potentially identifying information on participants, it is stored under restricted access. For more detailed information beyond the metadata and documentation provided, there is a process of managed access requiring the submission of a request for consideration. Please contact this email for data access: [email protected] Reporting guidelines: The manuscript adheres to STROBE checklist for observational cross-sectional studies. Acknowledgements We sincerely thank the study nurses for their dedication and hard work in sample and data collection. We are also deeply grateful to the caregivers and children for their invaluable participation and cooperation in this survey. Additionally, we thank Maximo Ramírez for his contribution in data management and Arnau Vañó-Boira for his contribution to sample processing and sequencing. References 1. World Health Organization: World Malaria Report 2023. World Health Organization; 2023. 2. Olumese P: WHO Malaria Guidelines: Treatment of Malaria.2023. 3. Adjei MR, Kubio C, Buamah M, et al. : Effectiveness of seasonal malaria chemoprevention in reducing under-five malaria morbidity and mortality in the Savannah Region, Ghana. Ghana Med. J. 2022 Jun 1; 56 (2): 64–70. PubMed Abstract | Publisher Full Text | Free Full Text 4. Berchie GO, Doe PF, Azu TD, et al. : Uptake and Effectiveness of Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine during Pregnancy in Africa: A Scoping Review. Diseases. 2024 Sep 4; 12 (9): 203. PubMed Abstract | Publisher Full Text | Free Full Text 5. Plowe CV: Malaria chemoprevention and drug resistance: A review of the literature and policy implications. Malar. J. 2022; 21 : 104. BioMed Central Ltd. PubMed Abstract | Publisher Full Text | Free Full Text 6. Peterson DS, Walliker D, Wellems TE: Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria (Plasmodiumfakiparum/drug resistance/folic acid antagonists/genetic linkage analysis/polymerase chain reaction). Proc. Nati. Acad. Sci. USA. 1988; 85 : 9114–9118. PubMed Abstract | Publisher Full Text | Free Full Text 7. Hyde JE: The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacol. Ther. 1990 Jan 1; 48 (1): 45–59. PubMed Abstract | Publisher Full Text 8. Nzila-Mounda A, Mberu EK, Sibley CH, et al. : Kenyan Plasmodium falciparum Field Isolates: Correlation between Pyrimethamine and Chlorcycloguanil Activity in vitro and Point Mutations in the Dihydrofolate Reductase Domain. Antimicrob. Agents Chemother. 1998; 42 (1): 164–169. PubMed Abstract | Publisher Full Text | Free Full Text 9. Happi CT, Gbotosho GO, Folarin OA, et al. : Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop. 2005 Sep; 95 (3): 183–193. PubMed Abstract | Publisher Full Text 10. Kublin JG, Witzig RS, Shankar AH, et al. : Molecular assays for surveillance of antifolate-resistant malaria. Lancet. 1998 May 30 [cited 2021 Mar 3]; 351 (9116): 1629–1630. PubMed Abstract | Publisher Full Text 11. van Eijk AM , Larsen DA, Kayentao K, et al. : Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: A systematic review and meta-analysis. Lancet Infect. Dis. 2019; 19 (5): 546–556. PubMed Abstract | Publisher Full Text 12. World Health Organization: Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019). Geneva: 2020. 13. Bassat Q, Alonso PL: Drug resistance in malaria in developing countries. Antimicrobial Resistance in Developing Countries. New York: Springer; 2010; pp. 95–116. 14. U.S. President’s Malaria Initiative: Sierra Leone Malaria Operational Plan FY 2023.2023. Reference Source 15. National Malaria Control Programme (Sierra Leone): Sierra Leone Malaria Indicator Survey 2016. Freetown, Sierra Leone: NMCP, SSL, CRS, and ICF; 2016. Freetown, Sierra Leone. 16. National Malaria Control Programme (Sierra Leone): Malaria Indicator Survey 2021 Final Report. Freetown, Sierra Leone: 2022. Reference Source 17. Government of Sierra Leone: Ministry of Health. Sierra Leone Malaria Control Strategic Plan 2016-2020.2015. 18. WHO list of Prequalified in vitro Diagnostic Products|WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control).[cited 2025 Mar 3]. Reference Source 19. Brokhattingen N, Matambisso G, da Silva C , et al. : Genomic malaria surveillance of antenatal care users detects reduced transmission following elimination interventions in Mozambique. Nat. Commun. 2024 Dec 1; 15 (1): 2402. PubMed Abstract | Publisher Full Text | Free Full Text 20. Mayor A, Serra-Casas E, Bardají A, et al. : Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women. Malar. J. 2009 Jan 9; 8 (1): 1–10. Publisher Full Text 21. Hermsen CC, Telgt DSC, Linders EHP, et al. : Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol. Biochem. Parasitol. 2001; 118 : 247–251. PubMed Abstract | Publisher Full Text Reference Source 22. Aranda-Díaz A, Vickers EN, Murie K, et al. : Sensitive and modular amplicon sequencing of Plasmodium falciparum diversity and resistance for research and public health. Sci. Rep. 2025 Mar 28; 15 : 10737. PubMed Abstract | Publisher Full Text | Free Full Text 23. Boene S, Rovira-Vallbona E, da Silva C , et al. : Antimalarial drug resistance and population structure of Plasmodium falciparum in Mozambique using genomic surveillance at health facilities (2021-2022).2024. Reference Source 24. GitHub - EPPIcenter/mad4hatter: [cited 2024 Feb 16]. Reference Source 25. mad4hatter/resources/v4/v4_reference.fasta at main · EPPIcenter/mad4hatter · GitHub: [cited 2025 Feb 19]. Reference Source 26. Firth D: Bias Reduction of Maximum Likelihood Estimates. Biometrika. 1993; 80 : 27–38. Accessed: 22/05/2008. Publisher Full Text Reference Source 27. Heinze G, Schemper M: A solution to the problem of separation in logistic regression. Stat. Med. 2002 Aug 30; 21 (16): 2409–2419. PubMed Abstract | Publisher Full Text 28. Length/height-for-age: [cited 2025 Mar 21]. Reference Source 29. Coveney J: FIRTHLOGIT: module to calculate bias reduction in logistic regression. Cobridge Co., Ltd; 2008. Reference Source 30. Fombah AE, Chen H, Owusu-Kyei K, et al. : Coverage of intermittent preventive treatment of malaria in infants after four years of implementation in Sierra Leone. Malar. J. 2023 Dec 1; 22 (1): 145. PubMed Abstract | Publisher Full Text | Free Full Text 31. Smith SJ, Kamara ARY, Sahr F, et al. : Efficacy of artemisinin-based combination therapies and prevalence of molecular markers associated with artemisinin, piperaquine and sulfadoxine-pyrimethamine resistance in Sierra Leone. Acta Trop. 2018 Sep 1; 185 : 363–370. PubMed Abstract | Publisher Full Text | Free Full Text 32. Lahuerta M, Sutton R, Mansaray A, et al. : Evaluation of health system readiness and coverage of intermittent preventive treatment of malaria in infants (IPTi) in Kambia district to inform national scale-up in Sierra Leone. Malar. J. 2021 Dec 1; 20 (1): 74. PubMed Abstract | Publisher Full Text | Free Full Text 33. Xu C, Sun H, Wei Q, et al. : Mutation Profile of pfdhfr and pfdhps in Plasmodium falciparum among Returned Chinese Migrant Workers from Africa. Antimicrob. Agents Chemother. 2019 May 1; 63 (5). PubMed Abstract | Publisher Full Text | Free Full Text 34. Lo AC, Faye B, Ba E-H, et al. : Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal.2013. Reference Source 35. Maiga H, Lasry E, Diarra M, et al. : Seasonal malaria chemoprevention with sulphadoxine-pyrimethamine and amodiaquine selects Pfdhfr-dhps quintuple mutant genotype in Mali. PLoS One. 2016 Sep 1; 11 (9): e0162718. PubMed Abstract | Publisher Full Text | Free Full Text 36. Amimo F, Lambert B, Magit A, et al. : Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in Africa: A systematic analysis of national trends. BMJ Glob. Health. 2020 Nov 19; 5 (11): e003217. PubMed Abstract | Publisher Full Text | Free Full Text 37. Leski TA, Taitt CR, Colston SM, et al. : Prevalence of malaria resistance-associated mutations in Plasmodium falciparum circulating in 2017–2018, Bo, Sierra Leone. Front. Microbiol. 2022 Dec 2; 13 . PubMed Abstract | Publisher Full Text | Free Full Text 38. Koko VS, Warsame M, Vonhm B, et al. : Artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: In vivo efficacy and frequency of molecular markers. Malar. J. 2022 Dec 1; 21 (1): 134. PubMed Abstract | Publisher Full Text | Free Full Text 39. Yobi DM, Kayiba NK, Mvumbi DM, et al. : Biennial surveillance of Plasmodium falciparum anti-malarial drug resistance markers in Democratic Republic of Congo, 2017 and 2019. BMC Infect. Dis. 2022 Dec 1; 22 (1): 145. PubMed Abstract | Publisher Full Text | Free Full Text 40. Berzosa P, Molina de la Fuente I, Ta-Tang TH, et al. : Temporal evolution of the resistance genotypes of Plasmodium falciparum in isolates from Equatorial Guinea during 20 years (1999 to 2019). Malar. J. 2021 Dec 1; 20 (1): 463. PubMed Abstract | Publisher Full Text | Free Full Text 41. Dorkenoo AM, Warsame M, Ataba E, et al. : Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine and prevalence of molecular markers of anti-malarial drug resistance in children in Togo in 2021. Malar. J. 2024 Dec 1; 23 (1): 92. PubMed Abstract | Publisher Full Text | Free Full Text 42. Okell LC, Reiter LM, Ebbe LS, et al. : Emerging implications of policies on malaria treatment: Genetic changes in the Pfmdr-1 gene affecting susceptibility to artemether–lumefantrine and artesunate–amodiaquine in Africa. BMJ Glob. Health. 2018 Nov 1; 3 (5): e000999. PubMed Abstract | Publisher Full Text | Free Full Text 43. Mensah BA, Aydemir O, Myers-Hansen JL, et al. : Antimalarial Drug Resistance Profiling of Plasmodium falciparum Infections in Ghana Using Molecular Inversion Probes and Next-Generation Sequencing.2020. 44. Konaté-Touré A, Gnagne AP, Bedia-Tanoh AV, et al. : Increase of Plasmodium falciparum parasites carrying lumefantrine-tolerance molecular markers and lack of South East Asian pfk13 artemisinin-resistance mutations in samples collected from 2013 to 2016 in Côte d’Ivoire. J. Parasit. Dis. 2024 Mar 1; 48 (1): 59–66. PubMed Abstract | Publisher Full Text | Free Full Text 45. Tarama CW, Soré H, Siribié M, et al. : Plasmodium falciparum drug resistance-associated mutations in isolates from children living in endemic areas of Burkina Faso. Malar. J. 2023 Dec 1; 22 (1): 213. PubMed Abstract | Publisher Full Text | Free Full Text 46. Venkatesan M, Gadalla NB, Stepniewska K, et al. : Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: Parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am. J. Trop. Med. Hyg. 2014 Oct 1; 91 (4): 833–843. PubMed Abstract | Publisher Full Text | Free Full Text 47. Humphreys GS, Merinopoulos I, Ahmed J, et al. : Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob. Agents Chemother. 2007 Mar; 51 (3): 991–997. PubMed Abstract | Publisher Full Text | Free Full Text 48. Sá JM, Twu O, Hayton K, et al. : Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Reference Source 49. Holmgren G, Hamrin J, Svärd J, et al. : Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect. Genet. Evol. 2007 Sep; 7 (5): 562–569. PubMed Abstract | Publisher Full Text 50. Uwimana A, Umulisa N, Venkatesan M, et al. : Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: An open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect. Dis. 2021 Aug 1 [cited 2024 Jul 9]; 21 (8): 1120–1128. PubMed Abstract | Publisher Full Text | Free Full Text Reference Source 51. Tumwebaze PK, Katairo T, Okitwi M, et al. : Drug susceptibility of Plasmodium falciparum in eastern Uganda: A longitudinal phenotypic and genotypic study. Lancet Microbe. 2021 Sep 1; 2 (9): e441–e449. PubMed Abstract | Publisher Full Text | Free Full Text 52. Mesia Kahunu G, Wellmann Thomsen S, Wellmann Thomsen L, et al. : Identification of the PfK13 mutations R561H and P441L in the Democratic Republic of Congo. Int. J. Infect. Dis. 2024 Feb 1; 139 : 41–49. PubMed Abstract | Publisher Full Text 53. Lamsfus Calle C, Schaumburg F, Rieck T, et al. : Slow clearance of histidine-rich protein-2 in Gabonese with uncomplicated malaria. Microbiol Spectr. 2024 Oct 3; 12 : e0099424. PubMed Abstract | Publisher Full Text | Free Full Text 54. Leski TA, Taitt CR, Swaray AG, et al. : Use of real-time multiplex PCR, malaria rapid diagnostic test and microscopy to investigate the prevalence of Plasmodium species among febrile hospital patients in Sierra Leone. Malar. J. 2020 Feb 21; 19 (1): 84. PubMed Abstract | Publisher Full Text | Free Full Text 55. World Health Organization: Updated WHO recommendations for malaria chemoprevention among children and pregnant women.2022 [cited 2024 Aug 23]. Reference Source Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 08 Oct 2025 ADD YOUR COMMENT Comment Author details Author details 1 ISGlobal, Barcelona, Spain 2 Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona, Barcelona, Spain 3 Centro de Investigacion Biomedica en Red de Epidemiologia y Salud Publica, Madrid, Community of Madrid, Spain 4 University of Sierra Leone College of Medicine and Allied Health Sciences, Freetown, Western Area, Sierra Leone 5 Ministry of Health, Freetown, Sierra Leone 6 Centro de Investigação em Saude de Manhiça, Manhiça, Maputo Province, Mozambique 7 Department of Physiological Sciences, Faculty of Medicine, Universidade Eduardo Mondlane, Maputo, Mozambique 8 Servicio de Salud Internacional, Hospital Clínic de Barcelona, Barcelona, Spain Haily Chen Roles: Conceptualization, Investigation, Methodology, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Kwabena Owusu-Kyei Roles: Conceptualization, Investigation, Methodology, Project Administration, Resources, Supervision, Writing – Review & Editing Augustin E. Fombah Roles: Investigation, Project Administration, Writing – Review & Editing Julian Williams Roles: Data Curation, Investigation, Supervision Carla García-Fernández Roles: Data Curation, Investigation, Supervision Eduard Rovira-Vallbona Roles: Conceptualization, Methodology, Software, Validation, Writing – Review & Editing Andreu Bofill Roles: Conceptualization, Data Curation, Formal Analysis, Software Llorenç Quintó Roles: Conceptualization, Formal Analysis, Software Antía Figueroa-Romero Roles: Formal Analysis, Writing – Review & Editing Falama Mac-Abdul Roles: Project Administration, Resources Mohamed Samai Roles: Conceptualization, Project Administration, Resources Alfredo Mayor Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Resources, Supervision, Validation, Writing – Review & Editing Clara Menéndez Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Resources, Supervision, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information This work was financially supported by the Gates Foundation (OPP1196642 and INV-067310, A.M.), La Caixa Foundation and the Departament d’Universitats i Recerca de la Generalitat de Catalunya (AGAUR; grant 2021 SGR 01517, A.M.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Article Versions (1) version 1 Published: 08 Oct 2025, 9:81 https://doi.org/10.12688/gatesopenres.16367.1 Copyright © 2025 Chen H et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads Gates Open Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Chen H, Owusu-Kyei K, Fombah AE et al. Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone . Gates Open Res 2025, 9 :81 ( https://doi.org/10.12688/gatesopenres.16367.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: AWAITING PEER REVIEW AWAITING PEER REVIEW ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 08 Oct 2025 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with Gates Open Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Prevalence of Molecular Markers of Resistance...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://gatesopenresearch.org/articles/9-81/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://gatesopenresearch.org/articles/9-81/v1&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://gatesopenresearch.org/articles/9-81/v1" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Chen H et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://gatesopenresearch.org/articles/9-81/v1/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://gatesopenresearch.org/articles/9-81", templates : { twitter : "Prevalence of Molecular Markers of Resistance to Antimalarial.... Chen H et al., published by " + "Gates Open Research" + ", https://gatesopenresearch.org/articles/9-81/v1" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/16367/17769") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "17769"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "b12b31f7-c9c7-424b-aaf6-2b7a1b5968bb"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); Are you a Gates-funded researcher? If you are a previous or current Gates grant holder, sign up for information about developments, publishing and publications from Gates Open Research. First Name * You must provide your first name Last Name * You must provide your last name Email * You must provide a valid email address Institution You must provide an institution. Submit Thank you! We'll keep you updated on any major new updates to Gates Open Research Gates Open Research Browse Gateways How to Publish About Contact Legal For Developers Cookie Notice Privacy Notice RSS Submit via VeriXiv © F1000 Research Limited and its licensors ISSN 2572-4754 var F1000platform = new F1000.Platform({ name: "gates", displayName: "Gates Open Research", hostName: "gatesopenresearch.org", id: "3", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });